Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company belonging to the Sandoz division of Novartis, to be directly marketed by ROVI in Germany.

Falithrom® is used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).

According to IQVIA, the 2017 net sales of the product in Germany totalled around 3.5 million euros. ROVI will pay Hexal nine million euros for the product.

Under this agreement, Falithrom® will be directly marketed by ROVI in Germany as soon as the administrative processes to authorize the transfer of the marketing authorization are completed before the German Federal Institute for Drugs and Medical Devices (BfArM).

Juan López-Belmonte Encina, ROVI’s CEO, commented: “With Falithrom®, ROVI reinforces its position in the anticoagulant market in Germany, the largest market in Europe, as part of its strategy to become a European player. Likewise, Falithrom® fully complements our existing portfolio and will be immediately accretive to our Germany subsidiary’s earnings”.